Evidence map›Paper›PMID 38515439›Full record

ArticleBrain communications2024

Brain dynamics predictive of response to psilocybin for treatment-resistant depression.

Jakub Vohryzek, Joana Cabral, Louis-David Lord, Henrique M Fernandes, Leor Roseman, David J Nutt, Robin L Carhart-Harris, Gustavo Deco, Morten L Kringelbach

Open access · goldAbstract read
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The psychedelic-peptide paradox: a hormetic hypothesis.Comprehensive psychoneuroendocrinology · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The flattening of spacetime hierarchy of theNational science review · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 7 countries.

Jakub VohryzekDepartment of Psychiatry, University of Oxford, Oxford, UK.
Joana CabralDepartment of Psychiatry, University of Oxford, Oxford, UK.
Louis-David LordDepartment of Psychiatry, University of Oxford, Oxford, UK.
Henrique M FernandesDepartment of Psychiatry, University of Oxford, Oxford, UK.
Leor RosemanCentre for Psychedelic Research, Department of Brain Sciences, Imperial College London, London, UK.
David J NuttCentre for Psychedelic Research, Department of Brain Sciences, Imperial College London, London, UK.
Robin L Carhart-HarrisCentre for Psychedelic Research, Department of Brain Sciences, Imperial College London, London, UK.
Gustavo DecoCenter for Brain and Cognition, Computational Neuroscience Group, Department of Information and Communication Technologies, Universitat Pompeu Fabra, Barcelona, Spain.
Morten L KringelbachDepartment of Psychiatry, University of Oxford, Oxford, UK.
Imperial College London · GBUniversity of Oxford · GBAarhus University · DKInstitució Catalana de Recerca i Estudis Avançats · ESPompeu Fabra University · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here, we leveraged the differential outcome in responders and non-responders to psilocybin (10 and 25 mg, 7 days apart) therapy for depression-to gain new insights into regions and networks implicated in the restoration of healthy brain dynamics. We used large-scale brain modelling to fit the spatiotemporal brain dynamics at rest in both responders and non-responders before treatment. Dynamic sensitivity analysis of systematic perturbation of these models enabled us to identify specific brain regions implicated in a transition from a depressive brain state to a healthy one. Binarizing the sample into treatment responders (>50% reduction in depressive symptoms) versus non-responders enabled us to identify a subset of regions implicated in this change. Interestingly, these regions correlate with

Indexed as

depressionlarge-scale brain modellingpsilocybin treatment

Identifiers

PMID38515439
PMCPMC10957168
OpenAlexW4391898793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.